The inspection, carried out between 5th and 13th of June 2023, was a cGMP Inspection and had ended with NIL observations.

Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company had reported 109.7% surge in net profit to Rs 1,086.9 crore in Q1 FY24 as compared with Rs 518.3 crore posted in Q1 FY23. Revenue from operations jumped 29.6% to Rs 5,139.6 crore during the quarter as compared with Rs 3,964.4 crore recorded in same quarter last year.